STI-9199
/ Sorrento
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 13, 2023
Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
(clinicaltrials.gov)
- P2 | N=0 | Withdrawn | Sponsor: Sorrento Therapeutics, Inc. | N=24 ➔ 0 | Trial completion date: Oct 2022 ➔ Oct 2024 | Initiation date: Apr 2022 ➔ Apr 2023 | Completed ➔ Withdrawn | Trial primary completion date: Jun 2022 ➔ Jun 2024
Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease
January 27, 2023
Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
(clinicaltrials.gov)
- P2 | N=24 | Completed | Sponsor: Sorrento Therapeutics, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Oct 2022
Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease
August 17, 2022
Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
(clinicaltrials.gov)
- P2 | N=24 | Active, not recruiting | Sponsor: Sorrento Therapeutics, Inc. | Not yet recruiting ➔ Active, not recruiting | N=700 ➔ 24 | Trial completion date: Jan 2023 ➔ Jul 2023 | Trial primary completion date: Jan 2023 ➔ Aug 2022
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
1 to 3
Of
3
Go to page
1